The FDA Oncologic Drugs Advisory Committee (ODAC) voted 11-0 with 1 abstention in favor of approval of Onyx (ONXX) multiple myeloma drug Kyprolis™(carfilzomib). The recommendation is for patients with relapsed and refractory multiple myeloma who have received at least two prior lines of therapy that included a proteasome inhibitor and an immunomodulatory agent (IMiD), the benefit-risk assessment is favorable for the use of Kyprolis™.  More...

When on February 24, 2012, we wrote that the Pharmacyclics (PCYC) story is one of only a few in which the power of the firm’s product pipeline overshadows the stock market’s technical influence, we were not hallucinating, as some have claimed. With this firm’s drug ibrutinib (PCI-32765) demonstrating safety and efficacy in various blood cancers, negative unsubstantiated speculations failed to persuade investors to cease investing in PCYC. Trial results have confirmed the superiority of ibrutinib in treating B-cell cancers, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), and multiple myeloma (MM).  More...

The media seems to have woken up from its unconsciousness, overlooking good news in favor of perpetrating negative energy that weighs heavily on people’s psyche. When undeniable cheerful realities emerge, the media can no more ignore it. That’s what we see happening at least in the biotechnology sector these days. Years of overlooking breakthrough approaches that demonstrate promise of improving the prognosis of cancers known to resist conventional treatments have ended and the negative media could not hide its admiration of what it is actually witnessing. Some would find a space to put a “BUT” after praising the drug, but investors have developed expertise in interpreting the but that is put in the wrong place. More...